Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
MOUNTAIN VIEW, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...
-
MOUNTAIN VIEW, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced that the Company has secured a credit facility of up to $100 million provided by Hercules...
-
MOUNTAIN VIEW, Calif., Jan. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...
-
MOUNTAIN VIEW, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...
-
-- Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks -- -- Significantly reduced...
-
-- Highlights Study Design, Outcome Measures, and Baseline Patient Data in the Ongoing Avacopan ACCOLADE Phase II Trial in C3G -- Reinforces Therapeutic Potential of Chemokine Receptor 2 (CCR2)...
-
-- Topline data from pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA vasculitis expected mid-to-late fourth quarter -- -- Awarded $1 million grant from the U.S. Food and...
-
MOUNTAIN VIEW, Calif., Oct. 28, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2019 financial results will be released after market...
-
MOUNTAIN VIEW, Calif., Sept. 24, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host an R&D Day on Tuesday, October 1, 2019 beginning at 12:00 p.m. ET...
-
MOUNTAIN VIEW, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two...